Novo Nordisk | NVO - Beneficio Operativo





Beneficio Operativo Cambio Fecha
ANI Pharmaceuticals USD 38.71M 9.58M 2026-03
Aurora Cannabis CAD -35.79M 19.88M 2025-12
Bausch Health Companies USD 489M 230M 2026-03
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Canopy Growth CAD -12.66M 1.64M 2025-12
Corcept Therapeutics USD -49.6M 54.09M 2026-03
Drreddys Laboratories INR 14.33B 2.51B 2025-12
Eli Lilly USD 9.78B 792M 2026-03
GlaxoSmithKline GBP 2.29B 856M 2026-03
Merck USD -1.88B 8.12B 2026-03
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Novartis USD 4.24B 171M 2026-03
Novo Nordisk DKK 59.62B 27.24B 2026-03
Novo Nordisk DKK 5.18B 33.61B 2025-06
Pacira USD 4.62M 1.43M 2026-03
Perrigo USD 33.6M 50.8M 2026-03
Phibro Animal Health USD 54.99M 2.36M 2025-12
Prestige Brands USD 82.49M 2.82M 2025-12
Sanofi EUR 1.94B 239M 2026-03
Supernus Pharmaceuticals USD -35.25M 49.07M 2026-03
Zoetis USD 865M 30M 2026-03